Acute extraperitoneal spontaneous bladder rupture in cervical cancer patient undergoing chemoradiation: A case report and review of the literature.

Bladder Cervix Chemoradiation Complications

Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 07 08 2020
revised: 22 09 2020
accepted: 30 09 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 23 10 2020
Statut: epublish

Résumé

The standard of care for locally advanced cervical cancer is pelvic radiotherapy with sensitizing cisplatin, and intracavitary brachytherapy. This standard of care treatment paradigm has best survival outcomes, however is associated with genitourinary toxicities. Spontaneous bladder rupture (SBR) is a rare complication of chemoradiation that has only been reported in literature as an intraperitoneal rupture occurring years after the cessation of treatment. We herein present a novel case of extraperitoneal SBR in a 27-year-old female with FIGO Stage IIIC cervical cancer and no prior surgical history who was undergoing chemoradiation with sensitizing cisplatin. During her final planned brachytherapy treatment upon instilling the bladder under ultrasound guidance, an anterior midline extraperitoneal rupture was noted. She was managed conservatively for several weeks and during this time was ultimately able to complete her external beam therapy and last cycle of cisplatin. After approximately ten weeks of conservative management, imaging demonstrated complete resolution of the rupture. A review of the literature suggests this complication tends to occur as an intraperitoneal rupture years after the cessation of therapy. Late genitourinary complications and types of complications are rarely reported in clinical trials, so it is difficult to determine the true incidence of rare complications and identify patients that may be at risk.

Identifiants

pubmed: 33088885
doi: 10.1016/j.gore.2020.100656
pii: S2352-5789(20)30122-3
pmc: PMC7566092
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100656

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

N Engl J Med. 1999 Apr 15;340(15):1144-53
pubmed: 10202165
Lancet. 2001 Sep 8;358(9284):781-6
pubmed: 11564482
J Med Case Rep. 2011 Jun 29;5:254
pubmed: 21714888
Electrolyte Blood Press. 2014 Jun;12(1):26-9
pubmed: 25061470
Gynecol Oncol. 1999 Jun;73(3):439-42
pubmed: 10366475
Radiat Med. 2000 Jul-Aug;18(4):261-5
pubmed: 11247004
Urology. 2018 Dec;122:1-9
pubmed: 30036617
J Clin Oncol. 2019 Sep 20;37(27):2472-2489
pubmed: 31403858
N Engl J Med. 1999 Apr 15;340(15):1137-43
pubmed: 10202164

Auteurs

Annalyn Welp (A)

Virginia Commonwealth University School of Medicine, Richmond, VA 23219, United States.

Emma C Fields (EC)

Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA 23219, United States.

Leslie Randall (L)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Virginia Commonwealth University Health System, Richmond, VA 23219, United States.

Florence K Brown (FK)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Virginia Commonwealth University Health System, Richmond, VA 23219, United States.

Stephanie A Sullivan (SA)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Virginia Commonwealth University Health System, Richmond, VA 23219, United States.

Classifications MeSH